Table Of Contents:

1. Market Context & Strategic Relevance
 1.1 Opening Context (Why the market matters)
  1.1.1 Why This Market Is Gaining Strategic Attention
  1.1.2 Business Decisions This Report Supports
 1.2 Scope
 1.3 Research & Methodology

2. Executive Summary
 2.1 Market Snapshot
 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035
 2.3 Market Size & Forecast, By Segmentation, 2022–2035
  2.3.1 Market Size By Analyte/Biomarker
  2.3.2 Market Size By Technology
  2.3.3 Market Size By Clinical Use Case
  2.3.4 Market Size By End User
 2.4 Market Share & Bps Analysis By Region, 2025
 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
 2.6 Industry CxO's Perspective

3. Market Overview
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Key Market Trends
 3.2 Industry PESTLE Analysis
 3.3 Key Industry Forces (Porter's) Impacting Market Growth
 3.4 Industry Supply Chain Analysis
  3.4.1. Component & Reagent Suppliers
  3.4.2. Liquid Biopsy Assay Manufacturers
  3.4.3. Distributors & Channel Partners
  3.4.4. End Users (Reference Laboratories, Hospitals, Oncology Clinics)
 3.5 Industry Life Cycle Assessment

4. Statistical Insights & Trends Reporting
 4.1 Clinical Performance & Diagnostic Accuracy Metrics
  4.1.1 Average Sensitivity of Liquid Biopsy for EGFR Mutation Detection in Lung Cancer (%)
  4.1.2 Average Specificity of Liquid Biopsy for Lung Cancer Biomarker Identification (%)
  4.1.3 Percentage Concordance Between Liquid Biopsy and Tissue Biopsy Results (%)
  4.1.4 Average Turnaround Time for Liquid Biopsy Results (Days)
  4.1.5 Rate of Successful ctDNA Detection in Early-Stage Lung Cancer Patients (%)
 4.2 Patient Management & Clinical Utility Indicators
  4.2.1 Percentage of Lung Cancer Patients Receiving Targeted Therapy Based on Liquid Biopsy Results (%)
  4.2.2 Average Reduction in Time to Treatment Initiation Through Liquid Biopsy Testing (Days)
  4.2.3 Percentage Increase in Clinical Trial Enrollment Using Liquid Biopsy for Patient Stratification (%)
  4.2.4 Average Number of Serial Liquid Biopsy Samples Collected Per Patient During Treatment Monitoring
  4.2.5 Percentage of MRD Monitoring Protocols Incorporating Liquid Biopsy in Clinical Practice (%)
 4.3 Technology Adoption & Testing Volume Metrics
  4.3.1 Share of NGS-Based vs. PCR-Based Liquid Biopsy Tests in Clinical Use (%)
  4.3.2 Percentage Growth in Liquid Biopsy Test Volume for Lung Cancer Year-over-Year (%)
  4.3.3 Average Adoption Rate of Fragmentomics/Methylation Signatures in Lung Cancer Testing (%)
  4.3.4 Percentage of Oncology Practices Integrating Liquid Biopsy Into Standard Care Pathways (%)
  4.3.5 Share of Liquid Biopsy Tests Utilized for Early Detection vs. Treatment Monitoring (%)
 4.4 Healthcare Economics & Reimbursement Indicators
  4.4.1 Average Cost Savings Per Patient Through Liquid Biopsy vs. Invasive Tissue Biopsy (USD)
  4.4.2 Percentage Reduction in Biopsy-Related Complications Through Liquid Biopsy Use (%)
  4.4.3 Percentage of Liquid Biopsy Tests Covered by Medicare/Private Insurance in Major Markets (%)
  4.4.4 Average Reimbursement Rate for Liquid Biopsy Profiling in Lung Cancer (USD)
  4.4.5 Percentage Reduction in Unnecessary Invasive Procedures Due to Liquid Biopsy Implementation (%)

5. Lung Cancer Liquid Biopsy Market Segmental Analysis & Forecast, By Analyte/Biomarker, 2022–2035, Value (USD Million)
 5.1 Introduction
 5.2 ctDNA
  5.2.1 Key Trends
  5.2.2 Market Size & Forecast, 2022 – 2035
 5.3 cfDNA
 5.4 CTCs
 5.5 Exosomes/Extracellular Vesicles
 5.6 Methylation/Fragmentomics Signatures

6. Lung Cancer Liquid Biopsy Market Segmental Analysis & Forecast, By Technology, 2022–2035, Value (USD Million)
 6.1 Introduction
 6.2 NGS-Based Comprehensive Genomic Profiling
  6.2.1 Key Trends
  6.2.2 Market Size & Forecast, 2022–2035
 6.3 PCR/ddPCR
 6.4 Fragmentomics/Methylation Analytics
 6.5 Others

7. Lung Cancer Liquid Biopsy Market Segmental Analysis & Forecast, By Clinical Use Case, 2022–2035, Value (USD Million)
 7.1 Introduction
 7.2 Therapy Selection
  7.2.1 Key Trends
  7.2.2 Market Size & Forecast, 2022–2035
 7.3 Treatment-Response Monitoring
 7.4 MRD/Recurrence Surveillance
 7.5 Early Detection/Screening

8. Lung Cancer Liquid Biopsy Market Segmental Analysis & Forecast, By End User, 2022–2035, Value (USD Million)
 8.1 Introduction
 8.2 Independent Reference Laboratories
  8.2.1 Key Trends
  8.2.2 Market Size & Forecast, 2022–2035
 8.3 Hospitals
 8.4 Oncology Clinics

9. Lung Cancer Liquid Biopsy Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Million)
 9.1 Introduction
 9.2 North America
  9.2.1 Key Trends
  9.2.2 Lung Cancer Liquid Biopsy Market Size & Forecast, By Analyte/Biomarker, 2022–2035
  9.2.3 Lung Cancer Liquid Biopsy Market Size & Forecast, By Technology, 2022–2035
  9.2.4 Lung Cancer Liquid Biopsy Market Size & Forecast, By Clinical Use Case, 2022–2035
  9.2.5 Lung Cancer Liquid Biopsy Market Size & Forecast, By End User, 2022–2035
  9.2.6 Lung Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035
   9.2.6.1 US
   9.2.6.2 Canada
 9.3 Europe
  9.3.1 Key Trends
  9.3.2 Lung Cancer Liquid Biopsy Market Size & Forecast, By Analyte/Biomarker, 2022–2035
  9.3.3 Lung Cancer Liquid Biopsy Market Size & Forecast, By Technology, 2022–2035
  9.3.4 Lung Cancer Liquid Biopsy Market Size & Forecast, By Clinical Use Case, 2022–2035
  9.3.5 Lung Cancer Liquid Biopsy Market Size & Forecast, By End User, 2022–2035
  9.3.6 Lung Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035
   9.3.6.1 Germany
   9.3.6.2 France
   9.3.6.3 UK
   9.3.6.4 Italy
   9.3.6.5 Spain
   9.3.6.6 Poland
   9.3.6.7 Russia
   9.3.6.8 Rest of Europe
 9.4 Asia Pacific
  9.4.1 Key Trends
  9.4.2 Lung Cancer Liquid Biopsy Market Size & Forecast, By Analyte/Biomarker, 2022–2035
  9.4.3 Lung Cancer Liquid Biopsy Market Size & Forecast, By Technology, 2022–2035
  9.4.4 Lung Cancer Liquid Biopsy Market Size & Forecast, By Clinical Use Case, 2022–2035
  9.4.5 Lung Cancer Liquid Biopsy Market Size & Forecast, By End User, 2022–2035
  9.4.6 Lung Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035
   9.4.6.1 China
   9.4.6.2 India
   9.4.6.3 Japan
   9.4.6.4 South Korea
   9.4.6.5 Australia
   9.4.6.6 ASEAN Countries
   9.4.6.7 Rest of Asia Pacific
 9.5 Latin America
  9.5.1 Key Trends
  9.5.2 Lung Cancer Liquid Biopsy Market Size & Forecast, By Analyte/Biomarker, 2022–2035
  9.5.3 Lung Cancer Liquid Biopsy Market Size & Forecast, By Technology, 2022–2035
  9.5.4 Lung Cancer Liquid Biopsy Market Size & Forecast, By Clinical Use Case, 2022–2035
  9.5.5 Lung Cancer Liquid Biopsy Market Size & Forecast, By End User, 2022–2035
  9.5.6 Lung Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035
   9.5.6.1 Brazil
   9.5.6.2 Argentina
   9.5.6.3 Mexico
   9.5.6.4 Colombia
   9.5.6.5 Rest of Latin America
 9.6 Middle East & Africa
  9.6.1 Key Trends
  9.6.2 Lung Cancer Liquid Biopsy Market Size & Forecast, By Analyte/Biomarker, 2022–2035
  9.6.3 Lung Cancer Liquid Biopsy Market Size & Forecast, By Technology, 2022–2035
  9.6.4 Lung Cancer Liquid Biopsy Market Size & Forecast, By Clinical Use Case, 2022–2035
  9.6.5 Lung Cancer Liquid Biopsy Market Size & Forecast, By End User, 2022–2035
  9.6.6 Lung Cancer Liquid Biopsy Market Size & Forecast, By Country, 2022–2035
   9.6.6.1 UAE
   9.6.6.2 Saudi Arabia
   9.6.6.3 Qatar
   9.6.6.4 South Africa
   9.6.6.5 Rest of Middle East & Africa

10. Competitive Landscape
 10.1 Key Players' Positioning
 10.2 Competitive Developments
  10.2.1 Year-Wise Strategies & Development, 2022–2026
 10.3 Market Share Analysis, 2025
 10.4 Product/Service & Application Benchmarking
  10.4.1 Product/Service Specifications & Features By Key Players
  10.4.2 Product/Service Heatmap By Key Players
  10.4.3 Application Heatmap By Key Players
 10.5 Industry Start-Up & Innovation Landscape
 10.6 Key Company Profiles
  10.6.1 Guardant Health, Inc.
   10.6.1.1 Company Overview & Snapshot
   10.6.1.2 Product/Service Portfolio
   10.6.1.3 Key Company Financials
   10.6.1.4 Geographical Presence
   10.6.1.5 SWOT Analysis
  10.6.2 F. Hoffmann-La Roche AG (Foundation Medicine)
  10.6.3 Thermo Fisher Scientific Inc.
  10.6.4 Natera, Inc.
  10.6.5 Illumina, Inc.
  10.6.6 Agilent Technologies, Inc.
  10.6.7 Bio-Rad Laboratories, Inc.
  10.6.8 Biocept, Inc.
  10.6.9 Burning Rock Biotech Limited
  10.6.10 Exact Sciences Corporation
  10.6.11 GRAIL, LLC
  10.6.12 Laboratory Corporation of America Holdings (Labcorp)
  10.6.13 Menarini Silicon Biosystems S.p.A.
  10.6.14 NeoGenomics, Inc.
  10.6.15 Personalis, Inc.
  10.6.16 QIAGEN N.V.
  10.6.17 Singlera Genomics, Inc.
  10.6.18 Tempus AI, Inc.
  10.6.19 Delfi Diagnostics, Inc.
  10.6.20 MDxHealth SA

11. Analyst Recommendations
 11.1 SNS Insider Opportunity Map
 11.2 Industry Low-Hanging Fruit Assessment
 11.3 Market Entry & Growth Strategy
 11.4 Analyst Viewpoint & Suggestions On Market Growth

12. Assumptions

13. Disclaimer

14. Appendix
 14.1 List Of Tables
 14.2 List Of Figures